Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 2
1964 1
1965 1
1967 1
1968 1
1970 1
1971 1
1974 1
1975 4
1979 2
1980 2
1981 2
1982 1
1983 1
1984 4
1985 8
1987 2
1988 3
1989 6
1990 5
1991 2
1992 1
1993 8
1994 4
1995 6
1996 6
1997 12
1998 11
1999 4
2000 7
2001 12
2002 11
2003 13
2004 13
2005 12
2006 12
2007 12
2008 12
2009 17
2010 15
2011 13
2012 12
2013 14
2014 15
2015 16
2016 17
2017 16
2018 22
2019 19
2020 15
2021 12
2022 11
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Psychiatry.
Sakamoto S, Kawai H, Okahisa Y, Tsutsui K, Kanbayashi T, Tanaka K, Mizuki Y, Takaki M, Yamada N. Sakamoto S, et al. Among authors: takaki m. Acta Med Okayama. 2019 Jun;73(3):189-195. doi: 10.18926/AMO/56860. Acta Med Okayama. 2019. PMID: 31235965 Free article. Review.
The chemistry and biology of guanidine natural products.
Berlinck RGS, Bertonha AF, Takaki M, Rodriguez JPG. Berlinck RGS, et al. Among authors: takaki m. Nat Prod Rep. 2017 Nov 15;34(11):1264-1301. doi: 10.1039/c7np00037e. Nat Prod Rep. 2017. PMID: 28967942 Review.
Heart slice NMR.
Uetani T, Yamashita D, Shimizu J, Misawa H, Tatematsu Y, Hamaguchi Y, Miyasaka T, Katanosaka Y, Kato T, Matsubara T, Furukawa K, Murohara T, Takaki M, Nakayama S. Uetani T, et al. Among authors: takaki m. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1181-6. doi: 10.1152/ajpheart.00923.2005. Epub 2006 Oct 13. Am J Physiol Heart Circ Physiol. 2007. PMID: 17040966 Free article.
Calcium-associated mechanisms in gut pacemaker activity.
Nakayama S, Kajioka S, Goto K, Takaki M, Liu HN. Nakayama S, et al. Among authors: takaki m. J Cell Mol Med. 2007 Sep-Oct;11(5):958-68. doi: 10.1111/j.1582-4934.2007.00107.x. J Cell Mol Med. 2007. PMID: 17979877 Free PMC article. Review.
[Sensitization phenomenon].
Ujike H, Takaki M. Ujike H, et al. Among authors: takaki m. Ryoikibetsu Shokogun Shirizu. 2003;(40):517-21. Ryoikibetsu Shokogun Shirizu. 2003. PMID: 14626174 Review. Japanese. No abstract available.
393 results